Home/ Supplements/ Omega 3/ Opti-EPA Liquid

Opti-EPA Liquid

product on market Liquid Douglas Laboratories Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • Limited research evidence available for ingredients
B Label Compliance Grade
Label

Product Label

Label for Opti-EPA Liquid
Open Full PDF View on NIH DSLD →
Details

Label Data

5 mL
Serving Size
48
Servings
Fat/Fatty Acid
Product Type
0%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Calories
40 {Calories}
Total Fat
4.5 g (7% DV)
Cholesterol
9 mg (3% DV)

Other Ingredients

Rosemary extract Ascorbyl Palmitate Vitamin E Natural flavors
Claims

Label Claims — Verification

Unverified All Other
Info

Product Information

Directions for Use

Suggested Usage: As a dietary supplement, take 1 teaspoon daily or as directed by your healthcare professional. Contents may appear cloudy when refrigerated.

Warnings & Precautions

Tamper resistant package, do not use if outer seal is missing.

KEEP OUT OF REACH OF CHILDREN.

Formulation Notes

This product contains fish oil (from anchovies and sardines).

This product contains NO yeast, wheat, gluten, soy protein, milk/dairy, corn, sodium, sugar, starch, artificial coloring, preservatives or flavoring.

Additional Information

Formula #99474

REFRIGERATE AFTER OPENING.

Metadata

Product Details

UPC / SKU3 10539 02657 1
DSLD Entry Date2012-06-25
Product TypeFat/Fatty Acid
FormLiquid
DSLD ID10442
Data Updated2026-04-11
Research

Research Evidence

495
Research Sources
56
Avg Quality
222
Meta Analysis
104
Clinical Trial
72
Rct
69
Systematic Review
11
Guideline
5
Cochrane Review
5
Regulatory Source
3
Narrative Review
1
Openfda Safety
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Omega-3 fatty acid addition during pregnancy
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for depression in adults
Systematic Review The Cochrane database of systematic reviews 2021 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Non-immunosuppressive treatment for IgA nephropathy
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Omega-3 fatty acid supplementation for depression in children and adolescents
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Interventions for fatigue and weight loss in adults with advanced progressive illness
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Motor control exercise for chronic non-specific low-back pain
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
View all evidence for Omega 3 →
Compare

Similar Products

View all Omega 3 products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.